Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE patients
It is very uncertain whether four‐food elimination and amino acid formula changes withdrawals due to adverse events at 6 weeks compared with four‐food elimination diet (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes withdrawal due to adverse events (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
It is very uncertain whether probiotics changes withdrawal due to adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine may leads to higher withdrawal due to adverse events compared with 5‐aminosalicylic acid (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in withdrawal due to adverse events compared with conventional dosing (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in withdrawal due to adverse events compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether once‐daily dosing changes withdrawal due to adverse events compared with conventional dosing (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in withdrawal due to adverse events compared with low dose 5‐ASA (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASA may leads to lower withdrawal due to adverse events compared with purine antimetabolites (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes withdrawal due to adverse events compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether sulphasalazine changes withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes withdrawal due to adverse events compared with no treatment (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether one‐food elimination diet changes withdrawals due to adverse events compared with six‐food elimination diet (very low certainty).
1 finding from 1 review